<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Summary:Stem cell transplantation (SCT) from a histocompatible sibling is treatment of choice for severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Survival rates have been reported to be as high as 90% for children </plain></SENT>
<SENT sid="2" pm="."><plain>Immunosuppressive therapy (IST) is employed in patients who are not candidates for SCT due to donor unavailability </plain></SENT>
<SENT sid="3" pm="."><plain>The addition of <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> to antilymphocyte globulin has improved the response rate to 70-80%, and survival at 5 years among responders is about 90% </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 30% of patients treated by IST suffer from relapse, but long-term prognosis does not appear to be affected by this complication </plain></SENT>
<SENT sid="5" pm="."><plain>Juvenile myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e>) shares both myelodysplastic and myeloproliferative features </plain></SENT>
<SENT sid="6" pm="."><plain>Survival (10-year) of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> without SCT is only 6% </plain></SENT>
<SENT sid="7" pm="."><plain>Children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> should be transplanted early in the course of their disease </plain></SENT>
<SENT sid="8" pm="."><plain>Conditioning regimen composed of three <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>, <z:chebi fb="0" ids="28901">busulfan</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and melphalan has been favored by the EWOG-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and EBMT-Pediatric WP in the second half of the 1990s </plain></SENT>
<SENT sid="9" pm="."><plain>SCT using this conditioning regimen is capable of curing approximately 50% of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>More than 70% of patients with refractory cytopenia and more than 50% of children with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are cured of by the early performed allogeneic SCT </plain></SENT>
</text></document>